In today’s briefing:
- Ohayo Japan | Wall Street Rallies as Tariff Concerns Ease
- Japan Morning Connection: Markets Swing Back to Risk on Potential for Watered Down Tariffs
- Semaglutide Patent Expiry: The Next Big Unlock in Global Pharma
- [Blue Lotus Non-US Internet Weekly, 12/52]: The Tug of War Between JD and Meituan Intensifies
- Monday Delight: 24/03/25
- #124 India Insight: Adani Eyes Cables, Piramal Targets $2B, World Bank Backs Rural Homes
Ohayo Japan | Wall Street Rallies as Tariff Concerns Ease
- US stocks rallied as Trump signalled softer tariffs, Tesla soared 12%, and Treasury yields rose. The US announced 25% tariffs on Venezuelan oil, pressuring China
- Sumitomo Real Estate hit a record high after reports that activist investor Elliott acquired shares and is in talks to enhance shareholder value.
- Hyundai Motor Group will invest 3.1 trillion yen in the U.S. over four years, including 900 billion yen for a Louisiana steel plant
Japan Morning Connection: Markets Swing Back to Risk on Potential for Watered Down Tariffs
- Tesla surging on the prospect for auto tariffs and semi’s up on the potential for leniency.
- US homebuilder woes continue with KB homes reporting a miss after market.
- Activist Elliott taking a stake in Sumitomo Reality may see holdings under pressure.
Semaglutide Patent Expiry: The Next Big Unlock in Global Pharma
- India’s pharma landscape is gearing up for a seismic shift as Semaglutide, used in diabetes and obesity, faces patent expiry in India by March 2026.
- With the global Semaglutide market expected to hit $56.75 billion by 2030, India’s low obesity drug penetration and cost-sensitive population make it a high-potential, underpenetrated market.
- The Semaglutide opportunity could rival Revlimid for Indian players. Natco, with FTF in the US. Expect multi-year growth runway, but execution, supply chain complexity, and regulatory hurdles remain key monitorables.
[Blue Lotus Non-US Internet Weekly, 12/52]: The Tug of War Between JD and Meituan Intensifies
- Our take is JD.com’s expansion to O2O/Food Delivery is still measured and constrained. It mainly serves the premium members;
- Meituan, PDD’ and Beike posted results broadly both in-line/slightly exceed expectations. Meituan and Beike raised AI capex while PDD and JD.com didn’t mention;
- Game received first official recognition in government’s 30 stimulative measures for consumption. Our TOP PICK is NTES.
Monday Delight: 24/03/25
- Each week, I’ll share five intriguing investment ideas that recently caught my attention. These ideas are meant to spark your research and help you kickstart the week ahead with fresh insights.
- Because these ideas are the result of my first-level idea generation process, they require more in depth research. Therefore, the ideas will often be concise, with occasional references to valuable work from other practitioners that I encourage you to explore.
- If you have something fascinating to share that could benefit me and the wider community, don’t hesitate to send it my way—I’d love to hear from you!
#124 India Insight: Adani Eyes Cables, Piramal Targets $2B, World Bank Backs Rural Homes
- Adani Group plans to enter the cables and wires segment, eyeing acquisitions worth $500-700 million.
- Piramal Pharma (PIRPHARM IN) aims $2B revenue by FY30, betting on CDMO growth, complex generics scale-up, and expanding consumer brands portfolio.
- World Bank to invest $500 million in India’s climate-resilient rural housing, supporting sustainability, innovation, and inclusive growth under PMAY-G.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
Unlock all research summaries